The many negative consequences of the COVID-19 pandemic especially on vulnerable groups like patients suffering from drug addiction have been anticipated by experts early on. While drug consumption patterns of patients in opioid substitution treatment (OST, N=24) seemed hardly influenced at the early stage of the pandemic in Austria, the impact on the mental health of this population remained unclear.

The main goal was to investigate long-term consequences of the pandemic in terms of PTSD and clinical symptoms of depression, anxiety and stress among patients in OST between December 2020 and February 2021.

In a cross-sectional survey study (N=123) an adapted version of the impact of event scale (IES-R) was applied to evaluate PTSD symptoms due to the COVID-19 pandemic. Clinical symptoms were assessed by the depression, anxiety and stress scale (DASS-21), and respective changes due to the pandemic were documented. Sociodemographic and COVID-19 related factors, as well as data on drug consumption patterns were collected.

A binary logistic regression analysis confirmed the negative long-term consequences of psychological and economic COVID-19 related factors on a higher risk for PTSD due to the pandemic. The high-risk PTSD group also demonstrated higher levels and a deterioration of depression, anxiety and stress symptoms since the pandemic.

Among our sample of patients in OST, 27% were at risk of PTSD due to the pandemic, and 30 to 50% reported concerning levels of depression, anxiety and stress. Health care facilities might use these findings as a valuable source of information, when special attention is needed.

No significant relationships.

Vulnerable groups like patients suffering from alcohol use disorders (AUD) are expected to be particularly affected by the negative consequences of the COVID-19 pandemic. In a prior study (N=127), we found that psychosocial COVID-19 factors and living alone elevated the probability for relapse during the initial stage of the pandemic, whereas long-term effects on mental health have yet to be investigated.

Here we aimed to investigate the risk of PTSD, as well as levels and developments in depression, anxiety and stress symptomatology as a consequence of the COVID-19 pandemic among patients with AUD.

Data was collected from a clinical sample of patients with AUD (N=136) in late 2020 and early 2021. PTSD symptoms due to the pandemic were assessed using an adapted version of the impact of event scale (IES-R). Levels in clinical symptoms were collected on the depression, anxiety and stress scale (DASS-21), and changes since the onset of the pandemic were assessed additionally.

The high-risk PTSD-group showed higher levels of depression, anxiety and stress, and reported more severe deteriorations in these symptoms, when compared to the low-risk group. A binary logistic regression model revealed psychological and social aspects of the pandemic to increase the probability for PTSD, whereas sociodemographic and other COVID-19 related factors showed no significant effects.

About 30% of patients with AUD indicated an elevated risk of PTSD due to the pandemic, as well as deteriorations in levels of depression, anxiety and stress. These concerning findings should be especially considered in current and future treatment settings.

No significant relationships.